PNNL's ASSORT model will help airports balance passenger screening and security risks with throughput. It also quantifies risks for different traveler types and optimizes checkpoint operations, improving efficiency while enhancing safety.

Researchers developed a robust, cost-effective, and easy-to-use cap-based technique for spatial proteome mapping, addressing the lack of accessible proteomics technologies for studying tissue heterogeneity and microenvironments.

Scientists are developing ways to detect previously unseen forms of fentanyl as well as other synthetic opioids known as nitazenes.

A cross-institutional team of scientists developed PeakQC, a new software tool for automated quality control of mass spectrometry data.

At the 2024 Aviation Futures Workshop, researchers from PNNL joined other subject matter experts and representatives from the stakeholder community in reimagining the passenger experience.

Ljiljana Paša-Tolić, a PNNL fellow, is the recipient of the 2024 International Mass Spectrometry Foundation’s Jochen Franzen Award. 

Scientists have developed a way to detect tiny amounts of hard-to-detect explosives more than eight feet away.

A team of researchers from Pacific Northwest National Laboratory and the Environmental Molecular Sciences Laboratory developed a new and flexible software tool called “Advanced Spectra PCA Toolbox.”

Researchers shared several technologies addressing urgent security challenges at the 2024 Homeland Protection Technologies Workshop at MIT Lincoln Laboratory, in Boston MA.

Vigorous exercise burns fat more in males than in females, but the benefits of exercise are broad for both sexes.

PNNL contributes to a nationwide research consortium investigating the molecular mechanisms triggered by endurance training.

Three PNNL-affiliated researchers have been named fellows of the American Association for the Advancement of Science, the world’s largest multidisciplinary scientific society.

Scientists have learned more about how to protect the insulin-producing cells that die in patients with Type 1 diabetes.

PNNL researchers helped identify a fragment from the SARS-CoV-2 virus that spurs severe illness.

Scientists have learned more about how drug resistance develops in patients with acute myeloid leukemia and how the process might be slowed.

PNNL scientists took thousands of measurements of firefighters in training to learn more about how the body responds to vigorous exercise.

Scientists have opened a new view into the workings of the central nervous system, finding a diverse set of important molecules.

Small teams in the Biological Sciences Division at PNNL and at EMSL—the Environmental and Molecular Sciences Laboratory, an Office of Science user facility at PNNL—are pros at preparation.

Scientists have taken an important step forward in predicting who will develop Type 1 diabetes months before symptoms appear.

Joshua Adkins and Jamie Lo will lead PMedIC, Pacific Northwest National Laboratory and Oregon Health & Science University’s joint research institute.